These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 28373293)

  • 1. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
    Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
    J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.
    Bayeva M; Sawicki KT; Ardehali H
    J Am Heart Assoc; 2013 Nov; 2(6):e000433. PubMed ID: 24275630
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.
    An D; Rodrigues B
    Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1489-506. PubMed ID: 16751293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipotoxicity in obesity and diabetes-related cardiac dysfunction.
    Zlobine I; Gopal K; Ussher JR
    Biochim Biophys Acta; 2016 Oct; 1861(10):1555-68. PubMed ID: 26899197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipotoxicity in type 2 diabetic cardiomyopathy.
    van de Weijer T; Schrauwen-Hinderling VB; Schrauwen P
    Cardiovasc Res; 2011 Oct; 92(1):10-8. PubMed ID: 21803867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
    Nakamura K; Miyoshi T; Yoshida M; Akagi S; Saito Y; Ejiri K; Matsuo N; Ichikawa K; Iwasaki K; Naito T; Namba Y; Yoshida M; Sugiyama H; Ito H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Progression of Diabetic Cardiomyopathy in OVE26 Type 1 Diabetic Mice.
    Tang X; Jiang S; Zhang J; Zhou S; Zheng Y
    Oxid Med Cell Longev; 2020; 2020():6961348. PubMed ID: 32509150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy.
    Ussher JR
    Expert Rev Cardiovasc Ther; 2014 Mar; 12(3):345-58. PubMed ID: 24552544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbreak my heart: targeting mitochondrial autophagy in diabetic cardiomyopathy.
    Kubli DA; Gustafsson ÅB
    Antioxid Redox Signal; 2015 Jun; 22(17):1527-44. PubMed ID: 25808102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
    Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes.
    Dong B; Qi D; Yang L; Huang Y; Xiao X; Tai N; Wen L; Wong FS
    Am J Physiol Heart Circ Physiol; 2012 Sep; 303(6):H732-42. PubMed ID: 22842069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes.
    Yan D; Cai Y; Luo J; Liu J; Li X; Ying F; Xie X; Xu A; Ma X; Xia Z
    J Cell Mol Med; 2020 Jul; 24(14):7850-7861. PubMed ID: 32450616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.
    Nandi SS; Mishra PK
    Adv Exp Med Biol; 2018; 1056():47-59. PubMed ID: 29754174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α.
    Liu F; Song R; Feng Y; Guo J; Chen Y; Zhang Y; Chen T; Wang Y; Huang Y; Li CY; Cao C; Zhang Y; Hu X; Xiao RP
    Circulation; 2015 Mar; 131(9):795-804. PubMed ID: 25637627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation.
    Yan X; Chen J; Zhang C; Zhou S; Zhang Z; Chen J; Feng W; Li X; Tan Y
    J Cell Mol Med; 2015 Jul; 19(7):1557-68. PubMed ID: 25823710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic Cardiomyopathy.
    Ni R; Zheng D; Xiong S; Hill DJ; Sun T; Gardiner RB; Fan GC; Lu Y; Abel ED; Greer PA; Peng T
    Diabetes; 2016 Jan; 65(1):255-68. PubMed ID: 26470784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
    Severson DL
    Can J Physiol Pharmacol; 2004 Oct; 82(10):813-23. PubMed ID: 15573141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial dysfunction in diabetic cardiomyopathy.
    Duncan JG
    Biochim Biophys Acta; 2011 Jul; 1813(7):1351-9. PubMed ID: 21256163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic cardiomyopathy: a brief summary on lipid toxicity.
    Ke J; Pan J; Lin H; Gu J
    ESC Heart Fail; 2023 Apr; 10(2):776-790. PubMed ID: 36369594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How exercise may amend metabolic disturbances in diabetic cardiomyopathy.
    Hafstad AD; Boardman N; Aasum E
    Antioxid Redox Signal; 2015 Jun; 22(17):1587-605. PubMed ID: 25738326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.